Aquestive Therapeutics Q2 2025 Earnings: EPS Loss of $0.14 Beats Estimates, Revenue Falls Short at $10 Million

Aquestive Therapeutics reported Q2 2025 earnings with revenue of $10mln, falling short of estimates, and an EPS loss of $0.14, beating estimates. The company's net loss was $13.5mln, up from $2.7mln in Q2 2024. Despite revenue challenges, Aquestive Therapeutics is focusing on advancing its product pipeline, including Anaphylm, for potential US and global launches in 2026.

Aquestive Therapeutics (AQST) reported its second-quarter 2025 earnings, revealing a quarterly loss of $0.14 per share, which surpassed the Zacks Consensus Estimate of a loss of $0.18 [1]. This represents an earnings surprise of +22.22%. The company's revenue for the quarter ended June 2025 was $10 million, falling short of the Zacks Consensus Estimate by 9.62%, compared to year-ago revenues of $20.1 million [1].

Despite the revenue shortfall, the company's net loss increased to $13.5 million from $2.7 million in Q2 2024. The company has focused on advancing its product pipeline, particularly its Anaphylm™ product, which received FDA acceptance of its New Drug Application (NDA) in the second quarter [3]. Anaphylm is an oral, sublingual film epinephrine product that, if approved, would be the first of its kind. The company plans to launch Anaphylm in the U.S. in 2026 and has begun initial regulatory engagements in Canada and the European Union [3].

The stock has gained about 9.6% since the beginning of the year, outperforming the S&P 500's gain of 8.6%. However, the sustainability of this performance will depend on the company's earnings outlook and management's commentary on the earnings call [1]. The current consensus EPS estimate for the coming quarter is -$0.17 on $12.33 million in revenues, and for the current fiscal year, it is -$0.72 on $45.27 million in revenues [1].

In the medical - drugs industry, which is currently in the top 35% of Zacks industries, the company's earnings outlook and industry trends will play a significant role in its stock performance [1]. VYNE Therapeutics Inc. (VYNE), another company in the same industry, is expected to post a quarterly loss of $0.23 per share in its upcoming report [1].

Aquestive Therapeutics will host an investor call on August 12, 2025, at 8:00am ET, where management will provide further insights into the company's financial performance and future prospects [3]. Investors should closely follow these developments to gauge the company's trajectory.

References:
[1] https://finance.yahoo.com/news/aquestive-therapeutics-aqst-reports-q2-225502521.html
[2] https://finance.yahoo.com/news/aquestive-therapeutics-inc-aqst-q2-133239601.html
[3] https://www.biospace.com/press-releases/aquestive-therapeutics-reports-second-quarter-2025-financial-results-and-provides-business-update